Journals / Ankara Sağlık Hizmetleri Dergisi / 2012 / Cilt: 11 - Sayı: 2

Serviks kanserinde radyoterapi tedavisinin yeri ve önemi

Pages
35–40
Publication Date
2012-10-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Suffered as a result of these studies, randomized trials that applied chemoradiotherapy implementation of chemoradiation in cervical cancer, especially cisplatin shown to provide a survival advantagein recent years, in order to increase the effectiveness of radiotherapy with chemoradiotherapy was introduced

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cervical cancer ranks second in terms of frequency of gynecological cancers.
📊
Key Findings & Data:Provides a low control rate in large tumors with external beam radiotherapy alone.
💡
Conclusion & Impact:Suffered as a result of these studies, randomized trials that applied chemoradiotherapy implementation of chemoradiation in cervical cancer, especially cisplatin shown to provide a survival advantagein recent years, in order to increase the effectiveness of radiotherapy with chemoradiotherapy was introduced
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Serviks kanseri · radyoterapi · kemoradyoterapi

Abstract

Cervical cancer ranks second in terms of frequency of gynecological cancers. Radiation therapy used to treat cervical cancer in the process nearly a century. In particular, became first-line treatment in locally advanced disease. Provides a low control rate in large tumors with external beam radiotherapy alone. Large tumors with the use of brachytherapy in cervical cancer control rates were also increased. The most common work chemoradiotherapy cisplatin, 5-FU and mitomycin-C, hydroxyurea, is used. Suffered as a result of these studies, randomized trials that applied chemoradiotherapy implementation of chemoradiation in cervical cancer, especially cisplatin shown to provide a survival advantagein recent years, in order to increase the effectiveness of radiotherapy with chemoradiotherapy was introduced

Özet

Serviks kanseri jinekolojik kanserler içinde sıklık açısından ikinci sırada yer almaktadır. Radyoterapi, yaklaşık yüzyıllık süreçte serviks kanseri tedavisinde kullanılmaktadır. Özellikle de lokal ileri hastalıkta ilk tedavi seçeneği olmuştur. Tek başına eksternal radyoterapi büyük tümörlerde düşük kontrol oranı sağlamaktadır. Serviks kanserinde brakiterapinin de kullanılması ile büyük tümörlerin kontrol oranları yükselmiştir. Son yıllarda radyoterapinin etkinliğini arttırmak amacıyla kemoradyoterapinin birlikte kullanımı gündeme gelmiştir. Kemoradyoterapi çalışmalarında en sık sisplatin, 5-FU, mitomisin-C ve hidroksiüre kullanılmıştır. Bu çalışmaların sonucunda kemoradyoterapinin uygulandığı randomize çalışmalarda görülmüştür ki serviks kanserinde kemoradyoterapi uygulanmasının, özellikle de sisplatinin sağkalım avantajı sağladığı gösterilmiştir

🔖

Cite This Article

YETMEN, Ö., AKTAŞ, C., B., H. B. (2012). Serviks kanserinde radyoterapi tedavisinin yeri ve önemi. Ankara Sağlık Hizmetleri Dergisi, Cilt: 11 - Sayı: 2, 35–40. https://ajindex.com/articles/115800

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Akine Y, Arimoto H, Ogino T, ve ark.1983. High dose rate intracavitary irradiation in the treatment of carcinoma of the uterine cervix:whole pelvis ırradiation and ıntracavitary radium. Int. J. Radiat Oncol Biol Phys. 9:367-71.
  2. Badib AO, Kurohara SS, Werteb JH, Pickren JW.1968. Metastasis to organs ın carcinoma of the uterine cervix:influence of treatment on incidebce and distribution. Cancer. 21:434 Carlson V, Delclos L, Fletcher GH. 1967.Distant metastases in squamous-cell carcinoma of the uterine cervix. Radiology 88:961 Chauvergne J, Rohart J, Heron JF, ve ark.1990.Randomised trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, M0). Bull Cancer. 77:1007-24.
  3. Dietmar Georg, Petra Georg, Martin Hillbrand, ve ark.2008. Assessment of ımproved organ at risk sparing for advanced cervix utilizing precision radiotherapy techniques. Strahlender Onkol.184:586 Eifel PJ, Winter K, Morris M, ve ark.2004. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high risk cervical cancer:an update of radiation therapy oncology group trial (Rtog) 90-01. J Clin Oncol.22:972-980.
  4. Grisby PW, Siegel Ba, Dehdashti F. 2001. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Gynecol. 19:3745-3749.
  5. Hamberger AD, Fletcher GH, Wharton JT.1978. Results of treatment of early stage I carcinoma of the uterine cervix with intracavitary radium alone. Cancer. 41(3):980-985.
  6. Heller PB, Malfenato JH, Bundy BN ve ark. 1990. Clinical-pathologic study of stage IIB, III and IVA carcinoma of the cervix: extended diagnostic evaluation for para-aortic node metastasis. Gynecol Onco.; 38:425-430.
  7. Horiot JC, Pigneux J, Pourquer H, Scaraub S, Achielle E, Keilling R, Combes P, Rozan R, Vrousos C, Daly N.1988. Radiotherapy alone in carcinoma of the intact uterine cervix according to G.H Fletcher guidelines: a french cooperative study off 1383 cases. Int J. Radit Oncol Biol Phys;14:605-611. Inoue T.1984. Prognostic significance of depth of invasion relating to nodal metastases, parametrial extension and cell types. a study of 628 cases with stage IB, IIA and IIB cervical carcinoma. Cancer: 3035 International Federation of Gynecology and Obstetrics.1995: Staging announcement figo staging of gynecologyic cancers: cervical and vulva. Int J Gynecol Cancer; 5:319-324.
  8. Keys HM, Bundy BN, Frederick BS ve ark. 1999.Cisplatin, radiation and adjuvant histerectomy compared with radiati